GPAT Gene Silencing in Muscle Reduces Diacylglycerols Content and Improves Insulin Action in Diet-Induced Insulin Resistance.
Iwona KojtaPiotr ZabielskiKamila Roszczyc-OwsiejczukMonika ImierskaEmilia SokołowskaAgnieszka Urszula Błachnio-ZabielskaPublished in: International journal of molecular sciences (2020)
Skeletal muscle is an important tissue responsible for glucose and lipid metabolism. High-fat diet (HFD) consumption is associated with the accumulation of bioactive lipids: long chain acyl-CoA, diacylglycerols (DAG) and ceramides. This leads to impaired insulin signaling in skeletal muscle. There is little data on the involvement of DAG in the development of these disorders. Therefore, to clarify this enigma, the gene encoding glycerol-3-phosphate acyltransferase enzyme (GPAT, responsible for DAG synthesis) was silenced through shRNA interference in the gastrocnemius muscle of animals with diet-induced insulin resistance. This work shows that HFD induces insulin resistance, which is accompanied by an increase in the concentration of plasma fatty acids and the level of bioactive lipids in muscle. The increase in these lipids inhibits the insulin pathway and reduces muscle glucose uptake. GPAT silencing through electroporation with shRNA plasmid leads to a reduction in DAG and triacylglycerol (TAG) content, an increase in the activity of the insulin pathway and glucose uptake without a significant effect on ceramide content. This work clearly shows that DAG accumulation has a significant effect on the induction of muscle insulin resistance and that inhibition of DAG synthesis through GPAT modulation may be a potential target in the treatment of insulin resistance.
Keyphrases
- insulin resistance
- skeletal muscle
- high fat diet
- type diabetes
- fatty acid
- glycemic control
- polycystic ovary syndrome
- blood glucose
- adipose tissue
- high fat diet induced
- metabolic syndrome
- escherichia coli
- electronic health record
- transcription factor
- machine learning
- climate change
- copy number
- big data
- combination therapy
- human health
- genome wide identification